Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
2 hedge funds and large institutions have $533K invested in Akero Therapeutics in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 258 closing their positions.
99% less funds holding
Funds holding: 265 → 2 (-263)
100% less capital invested
Capital invested by funds: $4.34B → $533K (-$4.34B)
100% less funds holding in top 10
Funds holding in top 10: 11 → 0 (-11)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 258
114.31% less ownership
Funds ownership: 114.34% → 0.02% (-114%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
+$478 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$298M |
| 2 |
GA
General Atlantic
New York
|
-$272M |
| 3 |
BlackRock
New York
|
-$271M |
| 4 |
RI
RTW Investments
New York
|
-$260M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$215M |
AKRO Hedge Fund Activity: Q4 2025 in Review
2 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q4 2025, worth a combined $533K — down 100% from $4.34B a quarter earlier.
Sellers outnumbered buyers: 258 funds closed out of AKRO and 0 opened new positions — a net loss of 258 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was IFP Advisors, adding an estimated $478. The largest seller was Janus Henderson Group, exiting entirely with an estimated $298M sold.
- 2 institutional investors held Akero Therapeutics (AKRO) as of Q4 2025, down from 265 in Q3 2025.
- Funds reported $533K of Akero Therapeutics stock for Q4 2025, down 100% quarter-over-quarter.
- 0 funds opened new Akero Therapeutics positions in Q4 2025 and 258 closed out, a net change of -258 holders.
- The largest Akero Therapeutics buyer in Q4 2025 was IFP Advisors, an estimated $478 added.
- The largest Akero Therapeutics seller in Q4 2025 was Janus Henderson Group, an estimated $298M sold.
Based on aggregated 13F filings for Q4 2025.